Abstracts tagged "Cardiovascular"

Abstract Number: 1428 • ACR Convergence 2021
Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², Punyasha Roul³, Shirley Cohen-Mekelberg², Bryant England³, Ted Mikuls³, Daniel Clauw⁴, Wyndy Wiitala², Rodney Hayward⁵, Jeremy Sussman⁶ and Akbar Waljee⁵, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ⁶University of Michigan; VA Ann Arbor Healthcare System; Center for Clinical Management Research, Ann Arbor, MI
Background/Purpose: A third of RA patients use long-term glucocorticoids (GCs) despite a known dose-dependent association with major adverse cardiovascular (CV) events (MACE). Prior work suggests…
Abstract Number: 0128 • ACR Convergence 2021
Increased Risk of Major Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus After Non-Cardiac Surgery
Sebastian Bruera¹, Xiudong Lei², Brandon Blau¹, Hui Zhao², Anita Deswal², Jinoos Yazdany³, Sharon Giordano² and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX, ³University of California San Francisco, San Francisco, CA
Background/Purpose: The association between systemic lupus erythematosus (SLE) and cardiovascular disease has been well-studied. Cardiovascular disease is a risk factor for major adverse cardiac events…
Abstract Number: 0287 • ACR Convergence 2021
20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compared to Diabetes
Reinder Raadsen¹, Rabia Agca², Alexandre Voskuyl³, Maarten Boers⁴, Willem Lems⁵, Arno van Kuijk¹ and Michael Nurmohamed², ¹Reade, Amsterdam, Netherlands, ²Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁵VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis have an increased risk for developing cardiovascular diseases (CVD) compared to the general population, similar to the CVD risk in…
Abstract Number: 0863 • ACR Convergence 2021
Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
Chi Chiu Mok¹, Ling Yin Ho², Kar Li Chan³, Sau Mei TSE² and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the predictive value of serum PCSK9 level on cardiovascular complications in Chinese patients with systemic lupus erythematosus (SLE).Methods: Consecutive patients who fulfilled…
Abstract Number: 1566 • ACR Convergence 2021
Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
Rachael Flood, Colm Kirby, David Kane and Ronan Mullan, Tallaght University Hospital, Dublin, Ireland
Background/Purpose: Vascular endothelial cells line the entire circulatory system, these cells have very distinct and unique functions that are paramount to vascular biology. Hyperuricemia has…
Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Thomas MacDonald¹, Isla Mackenzie¹, George Nuki² and Ian Ford³, ¹University of Dundee, Dundee, Scotland, United Kingdom, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
Abstract Number: 0496 • ACR Convergence 2020
A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease
David Patrick¹, Justin van Beusecum¹, Michelle Ormseth², Leslie J. Crofford², Sean Davies³, Sergey Dikalov¹ and David Harrison¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville
Background/Purpose: In SLE, cardiovascular complications are a significant contributor to morbidity and death. Importantly, there is an increased prevalence of hypertension in SLE patients compared…
Abstract Number: 1178 • ACR Convergence 2020
Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis
Genna Braverman¹, Sabahat Bokhari², Kazato Ito³, Joan Bathon² and Jon Giles⁴, ¹NY Presbyterian - Columbia University Irving Medical Center, New York, NY, ²Columbia University, Vagelos College of Physicians and Surgeons, New York, NY, ³Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁴Columbia University, New York, NY
Background/Purpose: The 400 meter timed walk test has been studied as a simple summary measure of fitness that is predictive of mobility limitation and incident…
Abstract Number: 1328 • ACR Convergence 2020
Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals…
Abstract Number: 1687 • ACR Convergence 2020
Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort
Monica Bray¹, Jennifer Rammel², Andrea Ramirez¹, Kristen Sexson¹, Fong Lam¹, Eyal Muscal³ and Marietta DeGuzman³, ¹Baylor College of Medicine, Houston, TX, ²University of Florida Health Jacksonville, Jacksonville, FL, ³Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…
Abstract Number: 0503 • ACR Convergence 2020
Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), are associated with increased cardiovascular (CV) risk. Metabolites comprise biomarkers that may add predictive value…
Abstract Number: 1179 • ACR Convergence 2020
Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study
Roxana Gonzalez Mazario¹, Jorge Juan Fragio Gil¹, Marta De la Rubia Navarro¹, Cristobal Pavez Perales¹, Samuel Leal Rodriguez², Jose Ivorra Cortes¹, Luis Gonzalez Puig³, Elena Grau Garcia², Elvira Vicens Bernabeu¹, F Ortiz-Sanjuan¹, Rosa Negueroles Albuixech¹, Cristina Alcañiz Escandell², Jose Eloy Oller Rodriguez¹, Inmaculada Chalmeta Verdejo¹, Isabel Martinez Cordellat¹, Carmen Najera Herranz¹, Ines Canovas Olmos¹, Antonio Cañada Martínez⁴ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain, ⁴HUP La Fe, Valencia, Spain
Background/Purpose: To assess the Cardiovascular Risk (CV) in Rheumatoid Arthritis (RA) patients using carotid ultasonography additionally to the traditional CV risk factors.Methods: A single center…
Abstract Number: 1330 • ACR Convergence 2020
Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients.
Inigo Gonzalez-Mazon¹, Javier Rueda-Gotor², Ivan Ferraz-Amaro³, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Fernanda Genre⁶, Natalia Palmou Fontana⁷, Vanesa Calvo-Río², Sara Remuzgo-Martínez⁶, Veronica Pulito-Cueto⁶, Alfonso Corrales⁸, Leticia Lera-Gómez⁶, Virginia Portilla⁶, Cristina Mata⁹, Vanesa Hernández-Hernández¹⁰, Santos Castañeda¹¹, Esther Francisca Vicente-Rabaneda¹², C Fernandez-Carballido¹³, M Paz Martínez-Vidal¹⁴, David Castro-Corredor¹⁵, Joaquín Anino-Fernández¹⁵, Juan Carlos Quevedo-Abeledo¹⁶, Carlos Rodríguez-Lozano¹⁷, María Luz García Vivar,¹⁸, Eva Galínez-Agirregoikoa¹⁸, C. Fernandez-Diaz¹⁹, Javier Llorca²⁰, Raquel López-Mejías⁶, Esther Montes-Perez²¹, Diana Peiteado²², Chamaida Plasencia²³, Alejandro Balsa-Criado²⁴, Nuria Barbarroja²⁵, Lourdes Ladehesa-Pineda²⁶, Rafaela Ortega-Castro²⁷, Eduardo Collantes-Estévez²⁶, Ricardo Blanco²⁸ and Miguel Ángel González-Gay²⁹, ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²H.U. Marques de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁶Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁷UNIVERSITARY HOSPITAL MARQUES VALDECILLA, Santander, Spain, ⁸Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital de Laredo, Santander, Spain, ¹⁰Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹¹Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ¹²Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ¹³H San Juan, Alicante, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹⁶Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁷Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁸Hospital Universitario Basurto, Bilbao, Spain, ¹⁹H. Marqués de Valdecilla, Madrid, Spain, ²⁰School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²¹Diagnóstico Médico Cantabria (DMC), Santander, Spain, ²²Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ²³Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ²⁴HOSPITAL UNIVERSITARIO LA PAZ, madrid, Spain, ²⁵Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ²⁷Hospital Universitario Reina Sofía, Córdoba, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) as compared to the general population. Carotid plaque, considered as a surrogate marker…
Abstract Number: 1689 • ACR Convergence 2020
Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abdulrahman Alkanhal¹, Joseph Saunders², Fajer Altammar³, Adam Huber⁴, Andrew Lynk², Alison MacLeod⁵, Oliva Ortiz-Alvarez⁶, Meighan Adams², Suzanne Ramsey⁷, Elizabeth Stringer⁸, Andrew Warren² and Bianca Lang⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Dalhousie University, Halifax, Canada, ³Mcmaster University, Hamilton, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Annapolis Valley Health, Kentville, Canada, ⁶St Martha's Regional Hospital, Antigonish, Canada, ⁷IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁸IWK Health Centre, Halifax, NS, Canada, ⁹Dalhousie University - Halifax, Halifax, NS, Canada
Background/Purpose: Kawasaki Disease (KD), a systemic vasculitis of unknown etiology, is now the leading cause of acquired heart disease in children in North America. Its…
Abstract Number: 0519 • ACR Convergence 2020
Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid
Rohan Willis¹, E Nigel Harris², Vijaya Murthy³, Zurina Romay-Penabad¹, Alvaro Schleh⁴, Monica Smikle², Karel De Ceulaer², Anne Tebo⁵, Troy Jaskowski⁶, Marta Guerra⁷, David Ware Branch⁸, Jane Salmon⁷, Michelle Petri⁹ and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³University of Texas Medical Branch, League City, TX, ⁴Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁵Department of Pathology, University of Utah, Salt Lake City, ⁶ARUP Laboratories, Salt Lake City, UT, ⁷Hospital for Special Surgery, New York, NY, ⁸University of Utah, Salt Lake City, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].